847818-71-7

Usage

Uses

Used in Pharmaceutical and Agrochemical Development:
1-(2-Methoxyethyl)-4-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole is used as a building block in the synthesis of pharmaceuticals and agrochemicals for its potential to contribute to the development of new drugs and pesticides. Its unique structure allows for the creation of a variety of compounds with different biological activities.
Used in Suzuki-Miyaura Cross-Coupling Reactions:
In the field of organic synthesis, 1-(2-Methoxyethyl)-4-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole is used as a reagent in Suzuki-Miyaura cross-coupling reactions. The boron atom in the molecule facilitates the formation of carbon-carbon bonds, which is crucial for constructing complex organic molecules and expanding the molecular diversity of synthesized compounds.
Used in Medicinal Chemistry Research:
Due to its potential biological activity, 1-(2-Methoxyethyl)-4-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole is utilized in medicinal chemistry research as a subject of interest. The pyrazole moiety in the compound may contribute to its interaction with biological targets, making it a promising candidate for the discovery of new therapeutic agents.

InChI:InChI=1/C12H21BN2O3/c1-11(2)12(3,4)18-13(17-11)10-8-14-15(9-10)6-7-16-5/h8-9H,6-7H2,1-5H3

Upstream product

• 76-09-5 2,3-dimethyl-2,3-butane diol 
• 847818-59-1 1-(2-methoxyethyl)-1H-pyrazol-4-ylboronic acid 
• 73183-34-3 bis(pinacol)diborane 
• 847818-49-9 4-bromo-1-(2-methoxyethyl)-1H-pyrazole 
• 61676-62-8 2-Isopropoxy-4,4,5,5-tetramethyl-1,3,2-dioxaborolane 
• 1407429-97-3 4-iodo-1-(2-methoxyethyl)-1H-pyrazole 
• 269410-08-4 pyrazole-4-boronic acid pinacol ester 
• 627-42-9 2-chloroethyl methyl ether 
• 6482-24-2 2-Bromoethyl methyl ether 

Downstream Products

• 1040376-75-7 3-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-[1-(2-methoxy-ethyl)-1H-pyrazol-4-yl]-2-methyl-pyridine 
• 1257994-16-3 diethyl (4-{[4-({7-[1-(2-methoxyethyl)-1H-pyrazol-4-yl]-2-methyl-3-oxo-2,3-dihydro-1H-isoindol-4-yl}amino)-5-(trifluoromethyl)pyrimidin-2-yl]amino}benzyl)phosphonate 
• 1352152-58-9 (S)-tert-butyl 1-(1-amino-3-(4-(1-(2-methoxyethyl)-1H-pyrazol-4-yl)phenyl)-1-oxopropan-2-ylcarbamoyl)cyclohexylcarbamate 

Relevant academic research and scientific papers

AMINOPYRIDINE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF

The present invention discloses an aminopyridine compounds, a preparation method and use thereof, particularly the aminopyridine compounds of formula (I), pharmaceutical compositions containing the same, the method for preparing the same and the use thereof in the prophylaxis or treatment of an adenosine A2a receptor related disease.

AMINOPYRAZINE COMPOUNDS AS HPK1 INHIBITOR AND THE USE THEREOF

Disclosed herein is an aminopyrazine compound of Formula (I), or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, and pharmaceutical compositions comprising thereof. Also disclosed is a method of treating HPK1 related disorders or diseases by using the compound disclosed herein.

MAP4K4 INHIBITORS

This invention relates to compounds that may be useful as inhibitors of Mitogen-activated Protein Kinase Kinase Kinase Kinase-4 (MAP4K4). The invention also relates to the use of these compounds, for example in a method of treatmentof cardiac conditions.In particular, the present invention relates to compounds of formula (I):

N-(AZAARYL)CYCLOLACTAM-1-CARBOXAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF

An N-(azaaryl)cyclolactam-1-carboxamide derivative having a structure of formula (I), a preparation method therefor, and a use thereof are disclosed in the application. Each substituent are defined in the specification and claims. The series of compounds of the application can be widely applied in the preparation of drugs for treating cancer, tumor, autoimmune disease, metabolic disease or metastatic disease, particularly for treating ovarian cancer, pancreatic cancer, prostate cancer, breast cancer, cervical cancer, glioblastoma, multiple myeloma, metabolic disease, neurodegenerative disease, primary tumor site metastasis or osseous metastasis cancer, and are expected to be developed into a new generation of CSF-1R inhibitor drugs.

Structure-based design and synthesis of 1H-pyrazolo[3,4-d]pyrimidin-4-amino derivatives as Janus kinase 3 inhibitors

Janus kinases (JAKs) regulate various inflammatory and immune responses and are targets for the treatment of inflammatory and immune diseases. Here we report the discovery and optimization of 1H-pyrazolo[3,4-d]pyrimidin-4-amino as covalent JAK3 inhibitors that exploit a unique cysteine (Cys909) residue in JAK3. Our optimization study gave compound 12a, which exhibited potent JAK3 inhibitory activity (IC50 of 6.2 nM) as well as excellent JAK kinase selectivity (>60-fold). In cellular assay, 12a exhibited potent immunomodulating effect on IL-2-stimulated T cell proliferation (IC50 of 9.4 μM). Further, compound 12a showed efficacy in delayed hypersensitivity assay. The data supports the further investigation of these compounds as novel JAKs inhibitors.

CARBOXYLIC ACID AROMATIC AMIDES AS ANTAGONISTS OF BRADYKININ B1 RECEPTOR

The present invention relates to carboxylic acid aromatic amides compounds of general formula (I) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing

Preparation and application of novel purine analogue JAK (janus kinase) inhibitor

The invention provides medicine for preventing, treating and/or relieving autoimmunity diseases such as Psoriasis, rheumatoid arthritis, inflammatory enteritis diseases, sjogren's syndrome, behcet's diseases, multiple sclerosis and systemic lupus erythematosus. The medicine has excellent JAK inhibitory activity. The invention also provides a medically acceptable composition containing the compoundand a method for preparing the compound.

PYRAZOLOPYRIMIDINE DERIVATIVES

The present invention covers Pyrazolopyrimidine compounds of general formula (I), in which n, o, X, Y, R, Q, R1, R2, R3 and R4 are as defined herein, methods of preparing said compounds, intermediate compounds u

Fused imidazole derivative having IDO/TDO inhibition activity and having structure represented by formula (I), preparation method and applications thereof

The present invention relates to a fused imidazole derivative having IDO/TDO inhibition activity and having a structure represented by a formula (I), a preparation method and applications thereof. According to the present invention, the series of the fused imidazole derivatives have high IDO/TDO inhibition activity, can be widely used for treating or preventing cancers or tumors, viral infections, depression, neurodegenerative disorders, trauma, age-related cataract, organ transplant rejections or autoimmune diseases, can further be used to inhibit the immune suppression of patients, and are expected to be developed into the new generation of the immunosuppressive agent. The formula (I) is defined in the specification.

Compounds used as JAK inhibitor, and use of compounds

The invention provides compounds used as a JAK inhibitor, and a use of the compounds, and concretely provides compounds (represented by formula (I)) with JAK inhibition activity or a stereoisomer, a geometric isomer, a tautomer, a racemate, a nitrogen oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, and a medicinal composition including the compounds. The invention also discloses a use of the compounds or the medicinal composition thereof in the preparation of medicines used for treating autoimmune diseases or proliferative diseases.